Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 10 2019
Historique:
received: 19 10 2018
revised: 15 02 2019
accepted: 11 03 2019
pubmed: 30 3 2019
medline: 6 2 2020
entrez: 30 3 2019
Statut: ppublish

Résumé

Soft tissue sarcomas (STS) are rare tumors accounting for less than 1% of human cancers. While the highest incidence of sarcomas is observed in elderly, this population is often excluded or poorly represented in clinical trials. The present study reports on clinicopathological presentation, and outcome of sarcoma patients over 90 recorded in the Netsarc.org French national database. NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor board (MDTB), funded by the French National Cancer Institute to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB, second pathological review, and collection of sarcoma patient characteristics and follow-up are collected in a database Information of patients registered from January 1, 2010, to December 31, 2016, in NETSARC were collected, analyzed and compared to the younger population. Patients with sarcomas aged >90 have almost exclusively sarcomas with complex genomics (92.0% vs. 66.3%), are less frequently metastatic (5.3% vs. 14·7%) at diagnosis, have more often superficial tumors (39.8% vs. 14.7%), as well as limbs and head and neck sites (75.2% vs. 38.7%) (all p < 0.001). Optimal diagnostic procedures and surgery were less frequently performed in patients over 90 (p < 0.001). These patients were less frequently operated in NETSARC centers, as compared to those of younger age groups including aged 80-90. However, local relapse-free survival, metastatic relapse-free survival and relapse-free survival were not significantly different from those of younger patients, in the whole cohort, as well as in the subgroup of operated patients. As expected overall survival was worse in patients over 90 (p < 0.001). Patients over 90 who were not operated had worse overall survival than younger patients (9.9 vs. 27.3 months, p < 0.001). Patients with STS diagnosed after 90 have distinct clinicopathological features, but comparable relapse-free survival, unless clinical practice guidelines recommendations are not applied. Standard management should be proposed to these patients if oncogeriatric status allows.

Identifiants

pubmed: 30924137
doi: 10.1002/ijc.32307
pmc: PMC6767526
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2135-2143

Informations de copyright

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

N Engl J Med. 1999 Dec 30;341(27):2061-7
pubmed: 10615079
PLoS One. 2011;6(8):e20294
pubmed: 21826194
J Pathol. 2011 Jan;223(1):64-71
pubmed: 21125665
Nat Rev Cancer. 2011 Jul 14;11(8):541-57
pubmed: 21753790
Nat Med. 2010 Jul;16(7):781-7
pubmed: 20581836
Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6
pubmed: 25210085
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
Clin Pract (Lond). 2014;11(6):749-762
pubmed: 25642321
Ann Oncol. 2013 Jul;24(7):1924-30
pubmed: 23493135

Auteurs

Clémence Basse (C)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Antoine Italiano (A)

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

Nicolas Penel (N)

Department of Medical Oncology, Centre Oscar Lambret, CHRU, Lille, France.

Olivier Mir (O)

Department of Orthopedic and Traumatology Surgery, University Hospital, Lille, France.

Claire Chemin (C)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Maud Toulmonde (M)

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

Florence Duffaud (F)

Department of Medical Oncology, Timone University Hospital, Marseille, France.

Axel Le Cesne (A)

Department of Medicine and Surgery, Gustave Roussy Cancer Campus, Paris, France.

Christine Chevreau (C)

Medical Oncology, University Institute of Cancerology, Toulouse, France.

Carlos Maynou (C)

Department of Medical Oncology, Centre Oscar Lambret, CHRU, Lille, France.

Philippe Anract (P)

Orthopaedic Department, Cochin University Hospital, Paris, France.

François Gouin (F)

Department of Orthopedic Surgery, Nantes University Hospital, Nantes, France.

Maria Rios (M)

Department of Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.

Nelly Firmin (N)

Department of Medicine, Val d'Aurelle Institute, Montpellier, France.

Jean-Emmanuel Kurtz (JE)

Medical Oncology & Orthopedy Department, Strasbourg University Hospital, Rennes, France.

Pierre Kerbrat (P)

Centre Eugène Marquis, Medical Oncology, Rennes, France.

Sophie Piperno-Neumann (S)

Department of Medical Oncology, Institut Curie, Paris, France.

François Bertucci (F)

Département of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.

Philippe Rosset (P)

Department of Orthopedic and Traumatology Surgery, Tours University Hospital, Tours, France.

Nicolas Isambert (N)

Centre Georges-Francois Leclerc, Dijon, France.

Emmanuelle Bompas (E)

Medical Oncology Department, René Gauducheau, Saint-Herblain, France.

Pascale Dubray-Longeras (P)

Centre Jean Perrin, Clermont-Ferrand, France.

Fabrice Fiorenza (F)

Department of Orthopedics Surgery and Traumatology, Limoges University Hospital, Limoges, France.

Christine Le Maignan (C)

Department of Dermatology and INSERM Unité 976, Saint Louis University Hospital, Paris, France.

Loïc Chaigneau (L)

Department of Medical Oncology, Jean Minjoz University Hospital, Besançon, France.

Antoine Thyss (A)

Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.

Olivier Bouché (O)

Institut Jean Godinot & Reims University Hospital, Reims, France.

Jean-Christophe Eymard (JC)

Institut Jean Godinot & Reims University Hospital, Reims, France.

Corinne Delcambre Lair (C)

Department of Medicine, François-Baclesse Institute, Caen, France.

Julien Adam (J)

Department of Medical Oncology, Timone University Hospital, Marseille, France.

Marie Karanian (M)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Céleste Lebbé (C)

Department of Dermatology and INSERM Unité 976, Saint Louis University Hospital, Paris, France.

Aurélien Dupré (A)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Pierre Meeus (P)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Mehdi Brahmi (M)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Armelle Dufresne (A)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Françoise Ducimetière (F)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Isabelle Ray-Coquard (I)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Jean-Yves Blay (JY)

Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH